This small-cap Pharma Inventory, engaged in manufacturing and R&D of prescription drugs, providing tablets, capsules, injectables, syrups, eye drops, and varied formulations, jumped 7 p.c after the corporate reported a web revenue progress of 43,516 p.c within the monetary yr 2025.
With a market capitalization of Rs. 9,172.13 crores, the share of Akums Medicine and Prescribed drugs Restricted has reached an intraday excessive of Rs. 620 per fairness share, rising almost 6.52 p.c from its earlier day’s shut worth of Rs. 582.05. Since then, the inventory has retreated and is presently buying and selling at Rs. 582.75 per fairness share.
Q4 FY25 Consequence Walkthrough:
Coming into the quarterly outcomes of Akums Medicine and Prescribed drugs Restricted, the corporate’s consolidated income from operations elevated by 11.79 p.c YOY, from Rs. 944.21 crore in Q4 FY24 to Rs. 1,055.55 crore in Q4 FY25, and grew by 4.47 p.c QoQ from Rs. 1,010.41 crore in Q3 FY25.
Akums Medicine and Prescribed drugs Restricted generated 79.44 p.c of its income from CDMO, 5.87 p.c from API, 9.14 p.c from home branded formulations, 3.50 p.c from worldwide branded formulations, and a couple of.05 p.c from commerce generics in Q4 FY25.
In Q4 FY25, Akums Medicine and Prescribed drugs Restricted’s consolidated web revenue has turned from unfavourable to constructive, from a web lack of Rs. 39.47 crore in Q4 FY24 to a web revenue of Rs. 149.61 crore in Q4 FY25. In comparison with Q3 FY25, the online revenue has elevated by 125.62 p.c, from Rs. 66.31 crore. The essential earnings per share elevated by 126.29 p.c and stood at Rs. 9.64 as towards Rs. 4.26 recorded within the earlier quarter within the monetary yr 2025.
FY25 Consequence: Akums Medicine and Prescribed drugs Restricted’s income has decreased from Rs. 4178.18 crore in FY24 to Rs. 4118.16 crore in FY25, which is a drop of 1.44 p.c. The web revenue has grown by 43,516.46 p.c, from Rs. 0.79 crore in FY24 to Rs. 343.78 crore in FY25.
Akums Medicine and Prescribed drugs Restricted was based in 2004 by Sanjeev Jain and Sandeep Jain. The corporate is a number one Indian pharmaceutical Contract Growth and Manufacturing Group (CDMO), serving each home and multinational pharmaceutical corporations.
The corporate operates 15 manufacturing services for several types of formulations and three services for energetic pharmaceutical components (APIs). It additionally has 4 R&D facilities in India. Its large product vary contains tablets, capsules, smooth gels, dry syrups, liquid orals, injectables, vials, ampoules, eye drops, and FFS formulations.
Written By – Nikhil Naik
Disclaimer
The views and funding ideas expressed by funding consultants/broking homes/ranking companies on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of monetary losses. Buyers should subsequently train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Personal Restricted or the writer will not be chargeable for any losses triggered on account of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.
The submit 43,516% revenue progress: Pharma Inventory jumps 7% after reporting robust Q4 outcomes appeared first on Commerce Brains.
